Evenamide boosts symptom improvement in treatment-resistant schizophrenia
Healio » Schizophrenia
by
3w ago
Evenamide, an investigational drug for treatment-resistant schizophrenia, was linked with “increasing, sustained and clinically significant” symptom improvements in a recent study, according to a manufacturer press release ..read more
Visit website
Brilaroxazine shows promise for schizophrenia in pivotal phase 3 trial
Healio » Schizophrenia
by
3w ago
Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer ..read more
Visit website
Study finds no associations between various mental health conditions and results after TJA
Healio » Schizophrenia
by
1M ago
Published results showed no statistically significant associations between mental health conditions, such as depression, anxiety, bipolar disorder, trauma and schizophrenia, and outcomes after total joint arthroplasty ..read more
Visit website
‘Don’t give up’: Catatonic woman wakes up after 20 years following treatment for lupus
Healio » Schizophrenia
by
1M ago
A woman diagnosed with schizophrenia and psychosis who was nonverbal and nonresponsive for 2 decades recently “woke” after treatment with pulse steroids and cyclophosphamide ..read more
Visit website
Karuna Therapeutics submits new drug application to FDA for schizophrenia treatment
Healio » Schizophrenia
by
1M ago
Karuna Therapeutics Inc. has submitted a new drug application to the FDA for KarXT, its investigational muscarinic antipsychotic for the treatment of schizophrenia ..read more
Visit website
Symptom dimensions within bipolar disorder may have distinct causes
Healio » Schizophrenia
by
3M ago
Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry ..read more
Visit website
Once-daily schizophrenia treatment falls short of endpoints in two phase 3 trials
Healio » Schizophrenia
by
3M ago
Two phase 3 studies of a once-daily treatment for schizophrenia failed to meet their primary endpoints, with developers pointing to placebo effects and disruption from the COVID-19 pandemic to possibly explain the drug’s performance ..read more
Visit website
KarXT reduces symptom severity in schizophrenia
Healio » Schizophrenia
by
5M ago
MIAMI BEACH, Fla. — Treatment with KarXT reduced symptom severity for those with schizophrenia and acute psychosis compared with placebo, according to research presented at the American Society of Clinical Psychopharmacology annual meeting ..read more
Visit website
Lifetime duration of cannabis use, cognition linked in schizophrenia
Healio » Schizophrenia
by
6M ago
SAN FRANCISCO — Among people with schizophrenia, lifetime duration of cannabis use was associated with cognitive function, according to a poster presented at the American Psychiatric Association annual meeting ..read more
Visit website
Higher rate of hip fractures found for patients with schizophrenia
Healio » Schizophrenia
by
6M ago
Patients with schizophrenia experienced earlier onset and higher rates of hip fractures compared with the general population, according to study results published in JAMA Network Open ..read more
Visit website

Follow Healio » Schizophrenia on FeedSpot

Continue with Google
Continue with Apple
OR